U.S. Antipsychotic Drugs Market Size, Trends, Share, and Growth Forecast, 2026 – 2033

The U.S. antipsychotic drugs market size is likely to be valued at US$8.2 billion in 2026 and is projected to reach US$12.1 billion by 2033, growing at a CAGR of 5.7% between 2026 and 2033. This steady growth is underpinned by the rising prevalence of mental health disorders and a shift toward Long-Acting Injectable (LAI) formulations that enhance patient adherence. The market is transitioning from traditional dopaminergic blockers to novel muscarinic agonists, which offer improved safety profiles and reduced metabolic side effects. Furthermore, expanded coverage under Medicare Part D reforms and increased federal funding for community mental health centers are providing stable institutional support for market expansion.